Products
- Solid Tumors
- Cardiovascular Diseases
- Hematological Malignancies
- Metabolic Diseases
- Neurological Diseases
- Pulmonary Diseases
- Diseased Tissue
- Circulating Nucelic Acids and Exosome Isolation
- Genomic DNA Isolation
- Cell Immortalization Products
- Immortalized Cell Lines
- Ready-to-Use Lentiviruses
- Reporter Cell Lines
New GPCR Cell Lines and Activity Assays
01/08/2013
Capital Biosciences is pleased to announce that it can now offer a number of ready-to-use stable cell lines expressing G-protein coupled receptors (GPCR) or cyclic nucleotide phosphodiesterases (PDEs) as usefull tools for drug screening. In addition reliable assays for GPCR or PDE activity based on ACTOne technology are also available.
Advantages of ACTOne Technology as the key platform used for the development of Cell Based Assay for GPCR and PDE:
- Use of a modified cyclic nucleotide-gated (CNG) ion channel as a biosensor
- Ultrasensitive response to cAMP fluctuations
- Suitable for high-throughput screening of GPCR-target molecules in living cells
- Companion assay kits available for easy use
- Cost effective system for drug discovery and other related studies
Commercial licensing for use of these cell lines in large scale screening of potential dug candidates is also available.